Research programme: monoclonal antibody conjugates - Stemline Therapeutics

Drug Profile

Research programme: monoclonal antibody conjugates - Stemline Therapeutics

Alternative Names: SL-101; SL-601

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Stemline Therapeutics
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
  • 12 Nov 2014 Stemline has patent protection for monoclonal antibody conjugates in USA
  • 14 Aug 2014 Preclinical development of SL 101 is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top